These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 12050534)

  • 1. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 2. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Diethylstilbesterol revised: androgen deprivation, osteoporosis and prostate cancer.
    Pitts WR
    J Urol; 2002 Nov; 168(5):2131-2. PubMed ID: 12394735
    [No Abstract]   [Full Text] [Related]  

  • 4. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
    Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
    N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
    Cai T; Bartoletti R
    J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
    [No Abstract]   [Full Text] [Related]  

  • 6. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer.
    Scherr D; Pitts WR; Vaughn ED
    J Urol; 2002 Feb; 167(2 Pt 1):535-8. PubMed ID: 11792913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone loss accompanying medical therapies.
    Dawson-Hughes B
    N Engl J Med; 2001 Sep; 345(13):989-91. PubMed ID: 11575293
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of treatment-related osteoporosis in men with prostate cancer.
    Smith MR
    Cancer Treat Rev; 2003 Jun; 29(3):211-8. PubMed ID: 12787715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effective therapy of the hot flashes during hormone withdrawal treatment in patients with advanced prostatic carcinoma].
    Kliesch S; Behre HM; Roth S
    Dtsch Med Wochenschr; 1997 Jul; 122(30):940-5. PubMed ID: 9280708
    [No Abstract]   [Full Text] [Related]  

  • 10. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
    Kudlacek S; Puntus T
    Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 12. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Pitts WR
    J Urol; 2003 Dec; 170(6 Pt 1):2392-3; author reply 2393-4. PubMed ID: 14634434
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
    Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
    Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Diethylstilbestrol revisited: androgen deprivation, osteoporosis and prostate cancer.
    Pitts WR
    J Urol; 2002 Oct; 168(4 Pt 1):1506-7. PubMed ID: 12352441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.